Insider · CIK 0001705295
David A Ford
Files at ICPT (INTERCEPT PHARMACEUTICALS, INC.), PRTA (PROTHENA CORP PUBLIC LTD CO). First filing -, latest -.
In brief
David A Ford files SEC Form 4 as officer at ICPT (INTERCEPT PHARMACEUTICALS, INC.), and also at PRTA (PROTHENA CORP PUBLIC LTD CO). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; David A Ford has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2025 | PRTA PROTHENA CORP PUBLIC LTD CO | AGrant or award Stock Option (Right to Buy)derivative | +107,500 | $0.00 | $0 | 107,500 | Mar 7, 2025 |
| Mar 1, 2024 | PRTA PROTHENA CORP PUBLIC LTD CO | AGrant or award Stock Option (Right to Buy)derivative | +85,000 | $0.00 | $0 | 85,000 | Mar 5, 2024 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | UTender of shares Common Stock | -15,038 | $19.00 | $286k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Common Stock | -21,400 | $19.00 | $407k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -11,300 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -16,000 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -3,480 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -8,520 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -6,463 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -3 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -900 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -5,200 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -5,900 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | ICPT INTERCEPT PHARMACEUTICALS, INC. | DDisposition to issuer Option to Purchase Common Stockderivative | -18,000 | - | - | 0 | Nov 13, 2023 |
Questions about David A Ford
Answered from the filings on this page, as of the latest one.
Is David A Ford buying or selling?
David A Ford has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did David A Ford's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David A Ford has 0.
Where does David A Ford file Form 4?
David A Ford has filed Form 4 at ICPT (INTERCEPT PHARMACEUTICALS, INC.) as Chief Human Resources Officer; PRTA (PROTHENA CORP PUBLIC LTD CO) as Chief People Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.